Clinical Trial Update: A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Tarceva to Avastin+Tarceva for EGFR-positive non-small cell lung cancer is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN